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Epithelial thyroid cancers are represented by the differentiated papillary and follicular thyroid carci-
nomas which, following dedifferentiation, are thought to give rise to the highly aggressive and incurable
anaplastic thyroid carcinomas. Although derived from the same cell type, the different thyroid tumors
show speciﬁc histological features, biological behavior and degree of differentiation as a consequence of
different genetic alterations. Over the last few years, our knowledge regarding the molecular alterations
underlying thyroid cell malignant transformation and cancer progression has considerably increased;
however, the prognosis of differentiated thyroid cancer patients still relies on high-risk clinic-patho-
logical variables. In particular, the actual staging systems provides only a rough prediction for cancer
mortality and risk of recurrences, including in each risk group patients with highly different tumor-
speciﬁc progression, disease-free interval and survival time. In order to improve DTC patient's risk
stratiﬁcation, both the European and the American Thyroid Associations proposed practical guidelines to
integrate the actual staging systems with additional clinical features such as the tumor histological
variant, the results of post-ablative whole body scan and the serum thyroglobulin levels. Despite that,
patients within the same risk group still show a very heterogeneous behavior in terms of disease-free
interval. As a consequence, the identiﬁcation of new prognostic molecular biomarkers able to testify
tumor aggressiveness is highly required. Here we'll review recently characterized newmolecular markers
potentially able to ameliorate the prognosis in DTC patients.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Thyroid cancer
Differentiated epithelial thyroid cancers (DTC) account for about
90e95% of all thyroid cancers and represent in the United States the
ﬁfth most common cancer inwomen [1,2]. The incidence of DTC has
been increasing over the last decades, mainly as a result of
the increasing ability to diagnosemalignant transformation in small
non-palpable nodules [3,4]. TheDTC comprise twomainhistological
entities, the follicular (FTC) and the papillary (PTC) thyroid carci-
nomas, which following dedifferentiation are assumed to generate
the poorly DTC (PDTC) and the highly aggressive anaplastic thyroid
carcinomas (ATC) unresponsive to any therapeutic agent [5,6]. Initiallisse).
by Elsevier Ltd. All rights reservedDTC treatment includes total thyroidectomy followed, in most pa-
tients, by adjuvant therapy with 131I [7e9]. Patient's follow-up
embraces radioiodine scanning 6e12 months after surgery, peri-
odic ultrasound of the thyroid bed and cervical lymph node com-
partments, measurement of basal and recombinant human TSH-
stimulated thyroglobulin (Tg) serum level [7e9].
2. Molecular events involved in thyroid cancer progression
Progression of human cancers, including DTC, is characterized
bymalignant cell acquisition of novel functional capabilities, which
include self-sufﬁciency in growth signals, insensitivity to anti-
growth signals, evasion of apoptosis, limitless replicative poten-
tial, sustained angiogenesis, tissue invasion and metastasis [10]. In
particular, relevant molecular alterations encountered in thyroid
cancer progression responsible for the acquisition of the above.
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kinase receptors, such as the RET/PTC and NTRK1 (neurotrophic
receptor-tyrosine kinase 1), or activating point mutations of pro-
teins mediating cellular responses to growth and differentiation
signals, including RAS and BRAF, or the oncogenic fusion protein
PAX8-PPARg, that suppresses wild-type PPARg function in a
dominant-negative manner [11,12]. Genomic instability, a hallmark
of solid tumors including the DTC, is thought to represent the mean
by which premalignant cells may acquire these new capabilities
[10,13]. As in many other cancer types, also in thyroid cancer the
number and the frequency of chromosomal abnormalities observed
increase from the DTC to the poorly differentiated thyroid carci-
noma (PDTC) and ATC [14,15]. It is worth to note that alterations in
the expression of several mitotic kinases responsible for correct
chromosome segregation have been described in both DTC and
ATC, and are thought to play a central role in the establishment of
genomic instability [14e17]. These include the Polo-like kinase 1
and the three members of the Aurora kinase family [18e20].
The conversion of early-stage thyroid tumors tomore aggressive
and invasive malignancies occurs through an epithelial-to-
mesenchymal transition (EMT), which implies the loss of cellecell
contacts, remodeling of cytoskeleton, and the acquisition of a
migratory phenotype [21,22]. Abnormal expression of integrins,
Notch, MET, TGFb, NF-kB, PI3K, TWIST1, matrix metalloproteinases
(MMP), components of the urokinase plasminogen activating sys-
tem and p21-activated kinase (Pak), involved in the EMT, have been
identiﬁed in PTC progression [21,22].
3. The prognosis of differentiated thyroid cancer patients
Differentiated thyroid cancer patients usually have a favorable
prognosis, with 10-years-survival rate of approximately 90%.
Nevertheless, about 20% of them face the morbidity of disease
recurrence and DTC-related deaths [1,2,23e25]. Despite the
increasing knowledge of the molecular processes responsible for
thyroid cell malignant transformation and cancer progression, to
date, the prognosis of thyroid cancer patients still relies on high-
risk clinic-pathological variables such as patient's age, tumor size,
histology, lymph nodal or distant metastasis [26,27]. In particular,
the TNM (Tumor size, lymph Node and distant Metastasis) system
developed by the American Joint Committee on Cancer and the
International Union Against Cancer is the most widely used staging
system for thyroid cancer patients [28]. This staging system is
strongly inﬂuenced by the patient's age, with those above 45 yr
receiving a worse prognosis despite other factors being equal [28].
The TNM, as well as other staging systems proposed by recognized
international organizations, are capable to make a rough prediction
of the high or low risk of cancer mortality leaving, however, in the
same risk group patients showing different disease-speciﬁc pro-
gression and survival time. Similarly, they fail to predict the risk of
cancer recurrences [29]. Both the European (ETA) and the American
Thyroid Associations (ATA) proposed practical guidelines to esti-
mate the risk of recurrences in which the TNM parameters are in-
tegrated by additional clinical features such as the tumor
histological variant, the results of post-ablative whole body scan
and the serum Tg levels [9,24]. Despite that, patients included in the
same risk group still show a very heterogeneous behavior in terms
of disease-free interval. In addition, the stratiﬁcation risk proposed
by the ATA and the ETA is not accurate in predicting the long-term
outcome in DTC patients, having a very low positive predictive
value [30]. As a consequence, the identiﬁcation of new prognostic
molecular biomarkers able to testify tumor aggressiveness is highly
required [31,32].
In this context, BRAFV600E mutation, the most prevalent genetic
alteration observed in 29e87% of PTC and considered as an earlygenetic event in thyroid cancer progression received considerable
attention as new prognostic marker in PTC [31e33]. However, its
association with older age, the detection of the mutation in lymph
node-metastasized PTC but not in primary tumors, and the recent
demonstration that BRAFV600E is a secondary subclonal rather than
a primary event in thyroid tumorigenesis, argue against the pro-
posed primary tumorigenic role of BRAFV600E in PTC [32,34,35].
Nevertheless, several reports described the association of this
mutation with factors related to poor prognosis, such as the pres-
ence of extrathyroidal extension, lymph node metastasis, advanced
tumor stage, reduced disease-free interval and patient survival
[31,33]. Despite the initial enthusiasm, a debate is actually ongoing
about the clinical relevance of these ﬁndings [31,32]. In particular,
some studies failed to associate the BRAFV600E with poor prognosis
in PTC patients [33,34,36]. In addition, the frequency of BRAF mu-
tation in PTC (on average 50%) is high compared with that of the
poor outcomes (about 20%). On the other hand, a recent case-study
performed on 977 patients affected by papillary microcarcinoma of
the thyroid suggested that the highly aggressive tumors may arise
in a subset of patients with the BRAFV600E [37]. From the currently
available information it is evident that, based only on the analysis of
the BRAFV600E mutation, a large percentage of patients would face
the risk of over- or under-treatment. Is thus possible that in a near
future the association of BRAFV600E with other clinical and/or mo-
lecular marker(s) could lead to a better prognostic deﬁnition of PTC
patients.
The urokinase plasminogen activating system (uPAS) comprises
the urokinase plasminogen activator (uPA), the cell membrane uPA
receptor (uPAR) and the plasminogen activator inhibitor-1 (PAI-1)
and -2 (PAI-2) [38]. It is involved on different aspects of human
cancer progression including extracellular matrix degradation,
activation of latent growth factors, malignant cells proliferation and
spread to distant metastatic sites, and tumor neo-angiogenesis
[38,39]. The prognostic value of uPAS has been demonstrated in
different cancer types where overexpression of one or more uPAS
components was shown to associate with a higher risk of relapse
and poor clinical outcome [38,39]. This is particularly evident in
breast cancer, in which uPA and PAI-1 show a predictive value
stronger than patient age, tumor size, estrogen and progesterone
receptors, HER-2/neu or p53 expression [40e44]. As a consequence,
the American Society of Clinical Oncology has included both pro-
teins among the recommended breast tumor markers for clinical
use [45]. Over the last two decades, several studies investigated the
expression of the uPAS in human thyrocytes [46e49]. Following
malignant thyrocyte transformation the aberrant expression of
uPAS components has been demonstrated [50e60]. More impor-
tantly, it has been evidenced that uPA, its cognate receptor uPAR
and PAI-1 signiﬁcantly associate with high-risk clinicopathological
factors such as lymph node metastasis, higher TNM stage, shorter
disease-free interval and overall survival [61e65]. Moreover, this
association was found statistically stronger in stage I patients
[34,61]. These ﬁndings may thus help to better deﬁne the prog-
nosis, make informed therapeutic decisions and develop tailored
prevention programs especially for stage I PTC patients, actually
considered at low risk to develop disease recurrences. All together
these observations indicate the potential prognostic value of uPAS
components in thyroid cancer patients, and warrant further in-
vestigations on larger case-studies.
The estrogen receptors (ER) are members of the nuclear steroid
receptor superfamily, and mediate cellular responses to estrogens
which modulate growth, differentiation and function of different
target tissues [66,67]. The ER function as ligand-dependent tran-
scription factors, but they can also have a ligand-independent ac-
tivity following phosphorylation by kinases [66,67]. Two different
genes encode the ER, ERa and ERb, showing different tissue
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cellular proliferation, migration and apoptosis [66,67]. The two ER
isoforms may also affect in different ways the development and
progression of human cancers, and have been shown to possess a
prognostic value in several cancer types including breast, ovarian
and lung cancers [68e76]. The expression of the ER has been also
described in both normal and neoplastic thyroid tissues and might
explain, at least in part, the higher prevalence of thyroid cancer in
females with respect to males [77e81]. Accordingly to this hy-
pothesis, Lee and colleagues showed that estradiol induces the
proliferation of PTC-derived cells when comparedwith cells treated
with testosterone, and that tamoxifene was able to attenuate the
growth-promoting effects of estradiol [82]. The proliferative effects
of estradiol on thyroid cancer cells seem to be mediated by the ERa,
as mimicked by ERa agonists, while ERb agonists inhibited cancer
cell proliferation [77]. This is in agreement with a recent study
showing that the expression of ERa in thyroid cancer is increased,
while that of ERb was undetectable [80]. In addition, Heikkil€a and
colleagues demonstrated that the reduction of ERb expression as-
sociates signiﬁcantly with poor outcome in FTC patients suggesting
its potential prognostic value in DTC patients [83].
Mature microRNAs (miR) are small (19e25 nucleotides), non-
coding RNA molecules that behave as negative regulators of gene
expression [84,85]. They regulate a wide variety of cellular func-
tions as proliferation and apoptosis and may act as either tumor
suppressor genes or oncogenes [84e88]. Mature miR typically
down-regulate gene expression post-transcriptionally by inhibiting
mRNA translation or promoting mRNA degradation by annealing to
complementary sequences in 30 untranslated regions of their target
mRNAs [85]. In thyroid cancer tissues different miRs were found
up-regulated and a number of them were suggested to have a
diagnostic utility [89e91]. In particular, the miR-146b was recently
shown to associate in PTC with extrathyroidal invasion, advanced
tumor stage, BRAF mutation and disease-free survival [92e97].
4. Conclusions and perspectives
In conclusion, different new promising molecular biomarkers
possibly capable to predict disease outcome in thyroid cancer pa-
tients are emerging. The experimental evidence here reported
warrant further clinical investigation to ﬁnally prove their prog-
nostic value. Their future inclusion in the clinical practice, alone or
in combination with conventional prognostic factors, is likely to
ameliorate the actual staging system, allowing a tailored follow-up
to the single patient needs.
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